Patients with congenital long QT syndrome who have survived a cardiac arrest represent a distinct, high-risk clinical group. The management approach in this scenario reflects the elevated risk of recurrence and the need for a structured, multi-component strategy.
The patient carries a diagnosis of congenital long QT syndrome and has experienced an aborted cardiac arrest — that is, they survived the event. Evidence shows that recurrence risk in this population remains substantial even while on standard pharmacological therapy, which directly shapes the treatment strategy applied here.
Management starts with a set of general avoidance measures, including avoidance of QT-prolonging drugs, correction of electrolyte abnormalities, and avoidance of genotype-specific arrhythmia triggers. Pharmacological therapy is central to the regimen, and device-based intervention is a key component of treatment in cardiac arrest survivors alongside pharmacotherapy. The full protocol details agent selection, sequencing, and specific criteria — see below.
For certain pharmacological options within this protocol, a specific response criterion involving the QTc interval is assessed before committing to chronic treatment. The exact threshold and testing procedure are described in the full protocol.
DOI: 10.1093/eurheartj/ehac262